Taiwanese biotech firms are aggressively integrating AI to shorten development cycles and enhance therapeutic efficacy across new drug discovery and medical aesthetics.

• Exosome Acceleration: Bionet (訊聯) has rebranded its digital unit to the "AI & Data Application Center." Its proprietary DeepExoMir engine has reduced exosome functional prediction times from months to hours—a 99.5% efficiency gain.
• Repurposing and Screening: Energenesis Biomedical (華安) will present its AI-driven drug repurposing platform at the NVIDIA GTC conference this March, aiming to identify 10 off-patent candidates annually. TaiGen (太景) has also partnered with Insilico Medicine to develop ISM4808, an AI-designed drug for CKD-related anemia.
• Precision and Aesthetics: aetherAI (雲象) and Ever Fortune. AI (長佳智能) are seeing increased hospital adoption of their AI diagnostic software. Meanwhile, Chlitina (麗豐-KY) and U-Neuron Biomedical (永立榮) are launching "AI Agents" and "Exosome Design Houses" to provide customized medical aesthetic formulations.

Resource: 生醫產業導入AI 戰力升級…訊聯、華安開發新藥